StockData
Zevra Therapeutics, Inc. logo

Zevra Therapeutics, Inc. (ZVRA) stock

ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.28−0.12 (-1.28%)

Close on Nov 18, 2026Market cap $551.08MP/E 10.0Yield –

Zevra Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Zevra Therapeutics's total assets was $302.71M at Jun 30, 2026. For fiscal 2025 it was $284.73M, up 59.8% from the year before. Over ten years it grew 18.0% a year on average. The highest annual figure on record is $284.73M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$284.73M+59.8%
FY2024Dec 31, 2024$178.13M+3.4%
FY2023Dec 31, 2023$172.33M+49.4%
FY2022Dec 31, 2022$115.34M-13.2%
FY2021Dec 31, 2021$132.94M+1086.0%
FY2020Dec 31, 2020$11.21M+6.7%
FY2019Dec 31, 2019$10.51M-60.7%
FY2018Dec 31, 2018$26.75M-49.0%
FY2017Dec 31, 2017$52.46M-38.2%
FY2016Dec 31, 2016$84.89M+55.5%
FY2015Dec 31, 2015$54.59M+298.1%
FY2014Dec 31, 2014$13.71M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$302.71M+18.1%
Q1 FY2026Mar 31, 2026$278.58M+61.3%
Q4 FY2025Dec 31, 2025$284.73M+59.8%
Q3 FY2025Sep 30, 2025$270.12M+41.0%
Q2 FY2025Jun 30, 2025$256.28M+77.5%
Q1 FY2025Mar 31, 2025$172.71M+14.2%
Q4 FY2024Dec 31, 2024$178.13M+3.4%
Q3 FY2024Sep 30, 2024$191.55M+37.8%
Q2 FY2024Jun 30, 2024$144.41M+36.9%
Q1 FY2024Mar 31, 2024$151.28M+41.9%
Q4 FY2023Dec 31, 2023$172.33M+49.4%
Q3 FY2023Sep 30, 2023$138.98M+16.3%
Q2 FY2023Jun 30, 2023$105.52M-15.1%
Q1 FY2023Mar 31, 2023$106.60M-15.2%
Q4 FY2022Dec 31, 2022$115.34M-13.2%
Q3 FY2022Sep 30, 2022$119.55M-12.9%
Q2 FY2022Jun 30, 2022$124.26M-10.5%
Q1 FY2022Mar 31, 2022$125.71M+39.0%
Q4 FY2021Dec 31, 2021$132.94M+1086.0%
Q3 FY2021Sep 30, 2021$137.19M+1124.4%
Q2 FY2021Jun 30, 2021$138.80M+1025.9%
Q1 FY2021Mar 31, 2021$90.44M+917.8%
Q4 FY2020Dec 31, 2020$11.21M+6.7%
Q3 FY2020Sep 30, 2020$11.20M-13.1%
Q2 FY2020Jun 30, 2020$12.33M-5.2%
Q1 FY2020Mar 31, 2020$8.89M-55.3%
Q4 FY2019Dec 31, 2019$10.51M-60.7%
Q3 FY2019Sep 30, 2019$12.89M-31.2%
Q2 FY2019Jun 30, 2019$13.01M-61.7%
Q1 FY2019Mar 31, 2019$19.87M-53.4%
Q4 FY2018Dec 31, 2018$26.75M-49.0%
Q3 FY2018Sep 30, 2018$18.74M-68.4%
Q2 FY2018Jun 30, 2018$34.00M-50.8%
Q1 FY2018Mar 31, 2018$42.65M-43.6%
Q4 FY2017Dec 31, 2017$52.46M-38.2%
Q3 FY2017Sep 30, 2017$59.31M-37.3%
Q2 FY2017Jun 30, 2017$69.05M–
Q1 FY2017Mar 31, 2017$75.64M–
Q4 FY2016Dec 31, 2016$84.89M–
Q3 FY2016Sep 30, 2016$94.54M–

More Zevra Therapeutics figures

See a number that looks wrong?